Most Read Articles
Naomi Rodrig, 15 Jun 2016
An interim analysis from the multinational phase III CASTOR trial, presented recently at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, showed that adding daratumumab to the standard two-drug regimen of bortezomib and dexamethasone markedly improved outcomes of patients with recurrent or refractory multiple myeloma.
Saras Ramiya, 14 Nov 2017
Accord Healthcare launches Accord Bortezomib® (bortezomib 3.5 mg per vial) for the treatment of patients with multiple myeloma and mantle cell lymphoma in Malaysia.
Su Ping Chuah, 01 Aug 2014

New immune therapies with new targets that can induce long-term remission in patients with advanced cutaneous T-cell lymphoma (CTCL) are needed, says an expert.

Radha Chitale, 01 Aug 2014

German experts came together to update guidelines on melanoma management and create consensus out of fragmented standards of care by experts across multiple fields.

Teen cancers on the rise since 1975

01 Mar 2017

Studies that seek to understand the causes of the spike in incidence of teen cancers is currently needed. Since 1975, there has been a 25-percent overall increase in teen cancers, particularly in testicular and thyroid cancer and non-Hodgkin's lymphoma due to unknown, probably multifactorial reasons.

The study used data from the 2015 Cancer Statistics Review by the SEER programme in order to describe cancer trends among individuals between the ages of 15 and 19. This included trends of histologic cancer groups and sites of cancer.

The rates of change of the annual incidence of teen cancers from 1975 to 2012 were calculated using linear regression analysis.

Such analyses showed that since 1975, incidence rates of cancers in teens increased at least until 2012. Specifically, cumulative incidence at all sites showed an increase of 0.62 percent for females and 0.67 percent for males annually.

In other words, the incidence rates for males and females in 2012, compared to those in 1975, rose by 28 and 26 percent, respectively. Furthermore, of the 4,900 teen cancers diagnosed in the US in 2012, 1,000 cases can be accounted for by this increasing trend.

In females, non-Hodgkin’s lymphoma (2.16 percent), thyroid cancer (2.12 percent) and acute myeloid leukaemia (1.73 percent) showed the greatest annual increase. In males, these were thyroid cancer (1.59 percent), testicular cancer (1.55 percent) and non-Hodgkin’s lymphoma (1.38 percent).

Further studies that explore the reasons behind this rise are needed in addressing this problem.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Naomi Rodrig, 15 Jun 2016
An interim analysis from the multinational phase III CASTOR trial, presented recently at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, showed that adding daratumumab to the standard two-drug regimen of bortezomib and dexamethasone markedly improved outcomes of patients with recurrent or refractory multiple myeloma.
Saras Ramiya, 14 Nov 2017
Accord Healthcare launches Accord Bortezomib® (bortezomib 3.5 mg per vial) for the treatment of patients with multiple myeloma and mantle cell lymphoma in Malaysia.
Su Ping Chuah, 01 Aug 2014

New immune therapies with new targets that can induce long-term remission in patients with advanced cutaneous T-cell lymphoma (CTCL) are needed, says an expert.

Radha Chitale, 01 Aug 2014

German experts came together to update guidelines on melanoma management and create consensus out of fragmented standards of care by experts across multiple fields.